PharmTech Drug Digest 11.20
|Articles|May 22, 2012

PDA Releases Technical Report on TBA and TCA Odors and Taints

Author(s)Susan Haigney

The Parenteral Drug Association has released guidance on the detection and mitigation of 2,4,6-tribromoanisole and 2,4,6-trichloroanisole taints and odors in pharmaceutical and healthcare products.

The Parenteral Drug Association (PDA) has released guidance on the detection and mitigation of 2,4,6-tribromoanisole (TBA) and 2,4,6-trichloroanisole (TCA) taints and odors in pharmaceutical and healthcare products.

Technical Report Number 55 (TR 55) provides information on the origin of TBA and TCA odors and taints, analytical methods developed, and risk-management strategies. The report highlights the uses of 2,4,6-tribromophenol (TBP) and 2,4,6-trichlorophenol (TCP); the role of fungal halophenol methylation that generates TBA and TCA haloanisole taints; and sensory and physiochemical properties of TBP, TCP, TBA, and TCA. The report also gives case examples of recalls, the root causes behind those recalls, and remedial actions taken.

From 2009 to 2011, companies in the pharmaceutical and consumer healthcare industries experienced product recalls due to the risk of product exposure to the TBA taint from tribromophenol-treated wood pallets. TR 55 offers “guidance on signal detection from adverse event and/or product quality complaints and resulting recalls, toxicology and safety, analytical method development and use, supply chain controls, risk analysis and mitigation.”

PDA members can access TR 55 for free until May 31, 2012.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.